Soiken Holdings Inc. (2385.T)
JPY 128.0
(-0.78%)
JPY 128.0
(-0.78%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 3.07 Billion JPY | 3.42% |
| 2022 | 2.99 Billion JPY | -2.01% |
| 2021 | 3.05 Billion JPY | -4.52% |
| 2020 | 3.19 Billion JPY | -0.11% |
| 2019 | 3.19 Billion JPY | 2.63% |
| 2018 | 3.11 Billion JPY | 11.46% |
| 2017 | 2.79 Billion JPY | 27.32% |
| 2016 | 2.19 Billion JPY | 29.81% |
| 2015 | 1.69 Billion JPY | 15.36% |
| 2014 | 1.46 Billion JPY | 7.17% |
| 2013 | 1.36 Billion JPY | 13.98% |
| 2012 | 1.2 Billion JPY | -1.02% |
| 2011 | 1.21 Billion JPY | -10.34% |
| 2010 | 1.35 Billion JPY | -19.43% |
| 2009 | 1.67 Billion JPY | 4.43% |
| 2008 | 1.6 Billion JPY | -12.48% |
| 2007 | 1.83 Billion JPY | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 Q4 | 691.76 Million JPY | 22.08% |
| 2023 FY | 3.09 Billion JPY | 3.42% |
| 2023 Q1 | 1.03 Billion JPY | 45.36% |
| 2023 Q2 | 796.23 Million JPY | -23.27% |
| 2023 Q3 | 566.65 Million JPY | -28.83% |
| 2022 Q1 | 1.01 Billion JPY | 44.27% |
| 2022 FY | 2.99 Billion JPY | -2.01% |
| 2022 Q4 | 713.89 Million JPY | 19.46% |
| 2022 Q3 | 597.61 Million JPY | -10.6% |
| 2022 Q2 | 668.5 Million JPY | -33.82% |
| 2021 Q3 | 570.84 Million JPY | -16.91% |
| 2021 Q2 | 687.04 Million JPY | -37.16% |
| 2021 Q1 | 1.09 Billion JPY | 42.38% |
| 2021 FY | 3.05 Billion JPY | -4.52% |
| 2021 Q4 | 700.19 Million JPY | 22.66% |
| 2020 Q2 | 761.37 Million JPY | -31.51% |
| 2020 Q1 | 1.11 Billion JPY | 74.58% |
| 2020 Q4 | 767.86 Million JPY | 38.35% |
| 2020 Q3 | 555.03 Million JPY | -27.1% |
| 2020 FY | 3.19 Billion JPY | -0.11% |
| 2019 Q4 | 636.75 Million JPY | 10.68% |
| 2019 FY | 3.19 Billion JPY | 2.63% |
| 2019 Q1 | 1.27 Billion JPY | 91.16% |
| 2019 Q2 | 711.31 Million JPY | -44.25% |
| 2019 Q3 | 575.3 Million JPY | -19.12% |
| 2018 Q4 | 667.48 Million JPY | 17.97% |
| 2018 Q2 | 670.8 Million JPY | -44.71% |
| 2018 FY | 3.11 Billion JPY | 11.46% |
| 2018 Q1 | 1.21 Billion JPY | 54.65% |
| 2018 Q3 | 565.8 Million JPY | -15.65% |
| 2017 Q3 | 529.33 Million JPY | -15.12% |
| 2017 Q2 | 623.65 Million JPY | -27.43% |
| 2017 FY | 2.79 Billion JPY | 27.32% |
| 2017 Q1 | 859.33 Million JPY | 49.35% |
| 2017 Q4 | 784.47 Million JPY | 48.2% |
| 2016 Q4 | 575.39 Million JPY | 35.88% |
| 2016 Q1 | 656.01 Million JPY | 22.6% |
| 2016 FY | 2.19 Billion JPY | 29.81% |
| 2016 Q2 | 541.76 Million JPY | -17.42% |
| 2016 Q3 | 423.44 Million JPY | -21.84% |
| 2015 FY | 1.69 Billion JPY | 15.36% |
| 2015 Q4 | 535.09 Million JPY | 46.61% |
| 2015 Q3 | 364.96 Million JPY | 5.11% |
| 2015 Q2 | 347.21 Million JPY | -21.95% |
| 2015 Q1 | 444.85 Million JPY | 58.24% |
| 2014 Q3 | 270.95 Million JPY | -19.21% |
| 2014 FY | 1.46 Billion JPY | 7.17% |
| 2014 Q4 | 281.13 Million JPY | 3.76% |
| 2014 Q1 | 579.29 Million JPY | 75.46% |
| 2014 Q2 | 335.38 Million JPY | -42.1% |
| 2013 Q3 | 285.12 Million JPY | -1.47% |
| 2013 Q1 | 463.99 Million JPY | 35.48% |
| 2013 Q2 | 289.37 Million JPY | -37.63% |
| 2013 Q4 | 330.16 Million JPY | 15.79% |
| 2013 FY | 1.36 Billion JPY | 13.98% |
| 2012 Q1 | 327.4 Million JPY | 5.85% |
| 2012 Q3 | 257.77 Million JPY | -5.61% |
| 2012 Q2 | 273.08 Million JPY | -16.59% |
| 2012 FY | 1.2 Billion JPY | -1.02% |
| 2012 Q4 | 342.48 Million JPY | 32.86% |
| 2011 FY | 1.21 Billion JPY | -10.34% |
| 2011 Q4 | 309.3 Million JPY | 20.68% |
| 2011 Q3 | 256.3 Million JPY | -25.46% |
| 2011 Q1 | 303.68 Million JPY | 2.89% |
| 2011 Q2 | 343.83 Million JPY | 13.22% |
| 2010 Q2 | 382.77 Million JPY | 1.01% |
| 2010 Q3 | 296.11 Million JPY | -22.64% |
| 2010 FY | 1.35 Billion JPY | -19.43% |
| 2010 Q4 | 295.14 Million JPY | -0.33% |
| 2010 Q1 | 378.93 Million JPY | -5.36% |
| 2009 Q4 | 400.41 Million JPY | 2.51% |
| 2009 FY | 1.67 Billion JPY | 4.43% |
| 2009 Q1 | 413.87 Million JPY | 2.48% |
| 2009 Q2 | 474.29 Million JPY | 14.6% |
| 2009 Q3 | 390.6 Million JPY | -17.64% |
| 2008 Q4 | 403.84 Million JPY | 16.46% |
| 2008 FY | 1.6 Billion JPY | -12.48% |
| 2008 Q2 | 398.84 Million JPY | -13.02% |
| 2008 Q1 | 458.54 Million JPY | 0.0% |
| 2008 Q3 | 346.76 Million JPY | -13.06% |
| 2007 FY | 1.83 Billion JPY | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 1.28 Billion JPY | -139.092% |
| PRISM BioLab Co.,LTD | 576.81 Million JPY | -432.419% |
| GNI Group Ltd. | 9.32 Billion JPY | 67.057% |
| Linical Co., Ltd. | 2.7 Billion JPY | -13.525% |
| Trans Genic Inc. | 2.15 Billion JPY | -42.191% |
| MEDINET Co., Ltd. | 1.49 Billion JPY | -105.952% |
| Cytori Cell Research Institute, Inc. | 1.85 Billion JPY | -65.38% |
| AnGes, Inc. | 8.9 Billion JPY | 65.502% |
| OncoTherapy Science, Inc. | 943.08 Million JPY | -225.642% |
| Nxera Pharma Co., Ltd. | 19.19 Billion JPY | 83.997% |
| Immuno-Biological Laboratories Co., Ltd. | 412.99 Million JPY | -643.618% |
| NanoCarrier Co., Ltd. | 975.37 Million JPY | -214.862% |
| Carna Biosciences, Inc. | 2.56 Billion JPY | -19.61% |
| CanBas Co., Ltd. | 278 Million JPY | -1004.701% |
| D. Western Therapeutics Institute, Inc. | 1.14 Billion JPY | -169.03% |
| RaQualia Pharma Inc. | 1.81 Billion JPY | -68.93% |
| Chiome Bioscience Inc. | 1.6 Billion JPY | -91.492% |
| Kidswell Bio Corporation | 2.37 Billion JPY | -29.359% |
| PeptiDream Inc. | 9.68 Billion JPY | 68.298% |
| Oncolys BioPharma Inc. | 1.96 Billion JPY | -56.64% |
| Ribomic Inc. | 1.1 Billion JPY | -177.751% |
| SanBio Company Limited | 4.53 Billion JPY | 32.34% |
| Healios K.K. | 3.48 Billion JPY | 11.928% |
| BrightPath Biotherapeutics Co., Ltd. | 1.15 Billion JPY | -165.954% |
| Kubota Pharmaceutical Holdings Co., Ltd. | 1.33 Billion JPY | -130.135% |
| Delta-Fly Pharma, Inc. | 1.4 Billion JPY | -118.821% |
| StemRIM | 2.07 Billion JPY | -47.932% |
| CellSource Co., Ltd. | 1.96 Billion JPY | -56.408% |
| FunPep Company Limited | 313.82 Million JPY | -878.606% |
| Kringle Pharma, Inc. | 958.01 Million JPY | -220.567% |
| Stella Pharma Corporation | 963.98 Million JPY | -218.581% |
| TMS Co., Ltd. | 943.25 Million JPY | -225.583% |
| Noile-Immune Biotech Inc. | 1.08 Billion JPY | -181.762% |
| Cuorips Inc. | 598.11 Million JPY | -413.456% |
| K Pharma,Inc. | 543.94 Million JPY | -464.595% |
| Takara Bio Inc. | 23.9 Billion JPY | 87.153% |
| ReproCELL Incorporated | 1.51 Billion JPY | -102.843% |
| PhoenixBio Co., Ltd. | 1.18 Billion JPY | -159.383% |
| StemCell Institute Inc. | 1.16 Billion JPY | -164.264% |
| Japan Tissue Engineering Co., Ltd. | 1.52 Billion JPY | -101.742% |
| CellSeed Inc. | 804.93 Million JPY | -281.532% |